Ovid Therapeutics Inc Cash Flow-to-Debt Ratio
Ovid Therapeutics Inc cash flow-to-debt ratio. Ovid Therapeutics Inc (OVID) has a Cash Flow-to-Debt Ratio of -0.80x as of June 2026, meaning its operating cash flow of $-17.59 Million could theoretically repay -1% of its total liabilities ($22.08 Million) in one year. Check cash flow quality index of Ovid Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ovid Therapeutics Inc (2014–2025)
Cash flow-to-debt ratio of Ovid Therapeutics Inc from 2014 to 2025. Historical debt coverage capacity for Ovid Therapeutics Inc across 12 annual periods. Check total reinvestment intensity of Ovid Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Ovid Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Ovid Therapeutics Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Ovid Therapeutics Inc. For the full cash flow conversion analysis, see OVID cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.89x | $-38.33 Million | $20.27 Million | ▲ +19.1% |
| 2024 | -2.34x | $-55.96 Million | $23.94 Million | ▼ -187.1% |
| 2023 | -0.81x | $-45.78 Million | $56.23 Million | ▲ +66.1% |
| 2022 | -2.40x | $-55.23 Million | $22.99 Million | ▼ -130.0% |
| 2021 | 8.02x | $118.61 Million | $14.80 Million | ▲ +601.8% |
| 2020 | -1.60x | $-51.58 Million | $32.29 Million | ▲ +66.2% |
| 2019 | -4.72x | $-51.09 Million | $10.82 Million | ▲ +8.3% |
| 2018 | -5.15x | $-45.56 Million | $8.84 Million | ▲ +1.4% |
| 2017 | -5.23x | $-31.47 Million | $6.02 Million | ▼ -9.6% |
| 2016 | -4.77x | $-17.80 Million | $3.73 Million | ▼ -100.7% |
| 2015 | -2.38x | $-5.49 Million | $2.31 Million | ▼ -9.1% |
| 2014 | -2.18x | $-261.28K | $119.95K | — |